BiondVax – executive interview

Published on 4 August 2022

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Elad Mark, BiondVax’s chief operating officer, discusses the company’s GMP biologics manufacturing facility and its suitability for the new NanoAb pipeline.

Share this with friends and colleagues